<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01166763</url>
  </required_header>
  <id_info>
    <org_study_id>11657</org_study_id>
    <nct_id>NCT01166763</nct_id>
  </id_info>
  <brief_title>Modulation of Breast Cancer Risk Biomarkers by High Dose Vitamin D</brief_title>
  <official_title>Modulation of Breast Cancer Risk Biomarkers by High Dose Vitamin D</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carol Fabian, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BTR Group</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this project is to determine if high dose vitamin D3 given to&#xD;
      premenopausal women at high risk for development of breast cancer, who initially have&#xD;
      insufficient levels of 25-hydroxy vitamin D (&lt;30 ng/ml), will raise 25(OH)D levels above 50&#xD;
      ng/ml. If so, will certain risk biomarkers for development of breast cancer be reliably and&#xD;
      favorably modulated?&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Protocol Objectives:&#xD;
&#xD;
      To determine if high dose vitamin D3 given to premenopausal women who initially have&#xD;
      insufficient levels of 25-hydroxy vitamin D (&lt;30 ng/ml) will raise 25(OH)D levels above the&#xD;
      50 ng/ml level considered to be required for breast health. If so, will certain risk&#xD;
      biomarkers for development of breast cancer be reliably and favorably modulated? The primary&#xD;
      endpoint will be a decrease in mammographic breast density (percent area considered at&#xD;
      increased density). Change in proliferation (a decrease as assessed by Ki-67) will also be&#xD;
      examined. Modulate of expression of genes important in breast cancer risk or reflective of&#xD;
      vitamin D's mechanism of action will be studied using quantitative real time polymerase chain&#xD;
      reaction (qRT-PCR).&#xD;
&#xD;
      Study Design:&#xD;
&#xD;
      The study is a single-arm open label clinical trial. Women who are high risk for development&#xD;
      of breast cancer on the basis of family or personal history will undergo random periareolar&#xD;
      fine needle aspiration (RPFNA) to acquire breast cells for assessment of gene expression by&#xD;
      qRT-PCR. Women with mammographic density &gt;10% will be eligible for enrollment. All subjects&#xD;
      will receive high dose vitamin D3 (3 capsules of 10,000 IU of vitamin D3 every week for 6-8&#xD;
      months). At that time, a repeat RPFNA and mammogram will be performed. Measurement of serum&#xD;
      levels of 25(OH)D will be performed at baseline, 3 months, and 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Mammographic Breast Density Over Course of Study</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>Change in the percent of the breast area that is considered to be at higher density on mammogram.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Proliferation (as Assessed by Ki-67) Examined in Breast Epithelial Cells.</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>Change in percent of cells expressing staining for Ki-67 antibody in breast epithelial cell specimens acquird by Random Periareolar Fine Needle Aspiration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OH Vitamin D Levels in Serum</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>Assessment of 25(OH)D levels as a measure of circulating vitamin D.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>high dose vitamin D3 (10,000 IU weekly)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group/Cohort Label vitamin D3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vitamin D3</intervention_name>
    <description>oral capsules, 10,000 IU per week for 6 months</description>
    <arm_group_label>high dose vitamin D3 (10,000 IU weekly)</arm_group_label>
    <other_name>Maximum D3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must be premenopausal women age 55 or younger, and actively menstruating with&#xD;
             4 or more periods per year.&#xD;
&#xD;
          -  Subjects may be using barrier contraceptive, an intrauterine device, a Nuvaring, or&#xD;
             similar non-oral contraceptive; or oral contraceptives.&#xD;
&#xD;
          -  Subjects must be at increased risk for breast cancer on the basis of at least one of&#xD;
             the following criteria:&#xD;
&#xD;
               -  five-year Gail risk of 3X the average risk of the age group;&#xD;
&#xD;
               -  a first degree relative with breast cancer under the age of 60 or multiple second&#xD;
                  degree relatives with breast cancer;&#xD;
&#xD;
               -  prior biopsy exhibiting atypical hyperplasia (AH), LCIS, DCIS, RPFNA evidence of&#xD;
                  hyperplasia with atypia within the last three years;&#xD;
&#xD;
               -  Chest or neck radiation before age 30;&#xD;
&#xD;
               -  Breast density equals or exceeds 50 percent.&#xD;
&#xD;
          -  If previously on a chemoprevention agent or prevention trial, subjects must have&#xD;
             completed study participation at least 6 months prior to baseline biomarker&#xD;
             assessment.&#xD;
&#xD;
          -  If subject has a history of AH, LCIS, or ER-positive DCIS by diagnostic biopsy, must&#xD;
             have been counseled about appropriate standard prevention therapies such as tamoxifen&#xD;
             and is either not eligible or is not interested in standard prevention therapies.&#xD;
             Women with DCIS must have had appropriate local therapy (lumpectomy plus radiation or&#xD;
             mastectomy).&#xD;
&#xD;
          -  Subject must have had a mammogram performed at the University of Kansas Breast Imaging&#xD;
             Center with estimated visual breast density of greater than 10 percent.&#xD;
&#xD;
          -  Subject must have had within six months prior to entering the study, an RPFNA during&#xD;
             the follicular portion (day 1-10) of the menstrual cycle with material for&#xD;
             cytomorphology, Ki-67 and qRT-PCR; in addition to serum obtained and banked.&#xD;
&#xD;
          -  Subjects must have 25(OH)D level &lt; 30 ng/ml as measured within 8 weeks of starting&#xD;
             intervention. Subjects may have been identified as having low vitamin D levels through&#xD;
             participation in HSC 11313, Osteopenia/Osteoporosis in Pre-menopausal Women at High&#xD;
             Risk for Development of Breast Cancer, but low level must be confirmed within 8 weeks&#xD;
             prior to starting study agent Subject must be willing to continue the same hormonal&#xD;
             milieu present at baseline throughout trial.&#xD;
&#xD;
          -  Subjects must be willing to undergo measurement of height, weight, and BMI at&#xD;
             initiation of intervention.&#xD;
&#xD;
          -  Subjects must have participated in HSC 11313, and have had a DEXA scan for bone&#xD;
             density and body fat analysis on the GE Lunar Prodigy Advance research unit in the&#xD;
             Breast Cancer Survivorship Center.&#xD;
&#xD;
          -  Subjects must be willing to sign an informed consent for the entire study and separate&#xD;
             consent for repeat RPFNA.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women that have had a metastatic malignancy of any kind.&#xD;
&#xD;
          -  Women that have had prior invasive breast cancer If subject has had a DCIS, at least&#xD;
             two months must have elapsed from surgery and/or radiation therapy to the involved&#xD;
             breast. Only the contra-lateral (uninvolved breast) will be studied by FNA. The&#xD;
             subject may not have had any radiation therapy to the contra-lateral breast to be&#xD;
             studied.&#xD;
&#xD;
          -  Women who are pregnant or nursing.&#xD;
&#xD;
          -  Women who have taken a SERM, aromatase inhibitor or participated in a chemoprevention&#xD;
             or other investigational drug study within six months prior to baseline FNA.&#xD;
&#xD;
          -  Women who have used fertility drugs within six months prior to baseline aspiration.&#xD;
&#xD;
          -  Women with a history of sarcoidosis, hypercalcemia, hyperparathyroidism, or renal&#xD;
             stones.&#xD;
&#xD;
          -  Women who are receiving treatment for rheumatoid arthritis or other connective tissue&#xD;
             diseases.&#xD;
&#xD;
          -  Women who have an elevated blood calcium level at baseline; defined as any elevation&#xD;
             above the institutional normal range.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carol Fabian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>July 16, 2010</study_first_submitted>
  <study_first_submitted_qc>July 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2010</study_first_posted>
  <results_first_submitted>January 27, 2014</results_first_submitted>
  <results_first_submitted_qc>January 27, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 10, 2014</results_first_posted>
  <last_update_submitted>June 16, 2016</last_update_submitted>
  <last_update_submitted_qc>June 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Carol Fabian, MD</investigator_full_name>
    <investigator_title>Professor, Director Breast Cancer Prevention Unit</investigator_title>
  </responsible_party>
  <keyword>breast atypia</keyword>
  <keyword>high risk for breast cancer</keyword>
  <keyword>random periareolar fine needle aspiration</keyword>
  <keyword>RPFNA</keyword>
  <keyword>breast epithelial hyperplasia</keyword>
  <keyword>ki-67</keyword>
  <keyword>chemoprevention</keyword>
  <keyword>vitamin D3</keyword>
  <keyword>Additional relevant MeSH terms:</keyword>
  <keyword>Molecular Mechanisms of Pharmacological Action</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Breast Neoplasms</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>Hyperplasia</keyword>
  <keyword>high risk for development of breast cancer</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Neoplasms by Site</keyword>
  <keyword>Pathologic Processes</keyword>
  <keyword>Antirheumatic Agents</keyword>
  <keyword>Breast Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Global results only will be published.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment April 2009 to December 2010. Breast Cancer Prevetnion Center at University of Kansas Medical Center</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>High Dose Vitamin D3 (10,000 IU Weekly)</title>
          <description>Group/Cohort Label vitamin D3&#xD;
vitamin D3: oral capsules, 10,000 IU per week for 6 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High Dose Vitamin D3 (10,000 IU Weekly)</title>
          <description>Group/Cohort Label vitamin D3&#xD;
vitamin D3: oral capsules, 10,000 IU per week for 6 months</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.4" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gail Risk 5-year Probability of Cancer Development</title>
          <description>Gail model is an algorithm to calculate a predicted probability of developing breast cancer within the next 5 years.</description>
          <units>percent probability</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.6" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Mammographic Breast Density Over Course of Study</title>
        <description>Change in the percent of the breast area that is considered to be at higher density on mammogram.</description>
        <time_frame>baseline and 6 months</time_frame>
        <population>All subjects completing trial</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D3 (10,000 IU Weekly)</title>
            <description>Group/Cohort Label vitamin D3&#xD;
vitamin D3: oral capsules, 10,000 IU per week for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mammographic Breast Density Over Course of Study</title>
          <description>Change in the percent of the breast area that is considered to be at higher density on mammogram.</description>
          <population>All subjects completing trial</population>
          <units>Change in percent dense breast area</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Proliferation (as Assessed by Ki-67) Examined in Breast Epithelial Cells.</title>
        <description>Change in percent of cells expressing staining for Ki-67 antibody in breast epithelial cell specimens acquird by Random Periareolar Fine Needle Aspiration.</description>
        <time_frame>baseline and 6 months</time_frame>
        <population>All subjects completing trial.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D3 (10,000 IU Weekly)</title>
            <description>Group/Cohort Label vitamin D3&#xD;
vitamin D3: oral capsules, 10,000 IU per week for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Proliferation (as Assessed by Ki-67) Examined in Breast Epithelial Cells.</title>
          <description>Change in percent of cells expressing staining for Ki-67 antibody in breast epithelial cell specimens acquird by Random Periareolar Fine Needle Aspiration.</description>
          <population>All subjects completing trial.</population>
          <units>percentage of cells staining positive</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" lower_limit="-4.0" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OH Vitamin D Levels in Serum</title>
        <description>Assessment of 25(OH)D levels as a measure of circulating vitamin D.</description>
        <time_frame>baseline and 6 months</time_frame>
        <population>All subjects completing trial</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D3 (10,000 IU Weekly)</title>
            <description>Group/Cohort Label vitamin D3&#xD;
vitamin D3: oral capsules, 10,000 IU per week for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>OH Vitamin D Levels in Serum</title>
          <description>Assessment of 25(OH)D levels as a measure of circulating vitamin D.</description>
          <population>All subjects completing trial</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.4" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months duration of study agent administration</time_frame>
      <group_list>
        <group group_id="E1">
          <title>High Dose Vitamin D3 (10,000 IU Weekly)</title>
          <description>Group/Cohort Label vitamin D3&#xD;
vitamin D3: oral capsules, 10,000 IU per week for 6 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTC 4</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <description>Grade 3, considered not to be related to study agent.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Increase in diarrhea</sub_title>
                <description>Grade 3, not considered to be related to study agent.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Flank pain</sub_title>
                <description>Grade 3 flank pain, not considered to be related to study agent</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTC 4</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal cramps</sub_title>
                <description>Grade 2 (2 instances in same subject)</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Grade 2 headache</description>
                <counts group_id="E1" events="30" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Single arm pilot trial so all comparisons are within subject for change over the course of the study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Bruce F. Kimler, Ph.D.</name_or_title>
      <organization>University of Kansas Medical Center</organization>
      <phone>913-588-4523</phone>
      <email>bkimler@kumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

